- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.03. | Aprea and MD Anderson sign agreement for APR-1051 | ||
| 11.03. | Vivus' Qsymia gains market approval in UAE for obesity treatment | ||
| 10.03. | UK MHRA approves Vertex's Alyftrek for cystic fibrosis | ||
| 07.03. | Relief Therapeutics and Renexxion terminate merger talks | ||
| 06.03. | CordenPharma announces $1bn investment in peptide development and production | ||
| 05.03. | FairJourney acquires Charles River's San Francisco site | ||
| 04.03. | FDA approves Celltrion's biosimilars for various indications | ||
| 03.03. | EMA's CHMP recommends marketing authorisation for Novartis' Fabhalta | ||
| 28.02. | FDA grants fast track status for Avobis' AVB-114 | ||
| 27.02. | China's NMPA approves Fosun's NDA of Tenapanor Hydrochloride tablets | ||
| 26.02. | Health Canada grants marketing authorisation to Kashiv's Pegfilgrastim | ||
| 25.02. | Biocon Biologics launches ustekinumab biosimilar in US | ||
| 24.02. | Tiziana Life Sciences partners with Renaissance for intranasal foralumab production | ||
| 21.02. | Genmab's epcoritamab gains approval in Japan for lymphoma treatment | ||
| 20.02. | Nona Biosciences partners with UAB to advance B Cell research | ||
| 19.02. | Perceive Pharma secures $15m to advance neuroprotective therapeutic development | ||
| 18.02. | SpringWorks Therapeutics selects Onco360 as pharmacy partner for Gomekli | ||
| 17.02. | US FDA approves Deciphera's Romvimza for TGCT treatment | ||
| 14.02. | Conduit and Charles River to evaluate AZD1656 in SLE model | ||
| 13.02. | ExpressionEdits and Boehringer Ingelheim partner to optimise gene therapies | ||
| 12.02. | FDA to review Regeneron's linvoseltamab BLA for multiple myeloma treatment | ||
| 11.02. | AdvanCell, Lilly partner on new targeted alpha therapies for cancer treatment | ||
| 10.02. | Norgine launches sodium thiosulfate injection in Germany | ||
| 07.02. | Essential and Clinigen expand JAPAC partnership to drive patient access | ||
| 06.02. | DEBRA Research and LEO Pharma partner for skin disease therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .